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IschemiaPeriostin, an extracellularmatrix protein, is expressed in injured tissues, such as the heartwithmyocardial infarc-
tion, and promotes angiogenesis and tissue repair. However, themolecularmechanism associatedwith periostin-
stimulated angiogenesis and tissue repair is still unclear. In order to clarify the role of periostin in neovasculari-
zation, we examined the effect of periostin in angiogenic potentials of human endothelial colony forming cells
(ECFCs) in vitro and in an ischemic limb animal model. Recombinant periostin protein stimulated the migration
and tube formation of ECFCs. To identify the functional domains of periostin implicated in angiogenesis, ﬁve frag-
ments of periostin, including four repeating FAS-1 domains and a carboxyl terminal domain, were expressed in
Escherichia coli and puriﬁed to homogeneity. Of the ﬁve different domains, the ﬁrst FAS-1 domain stimulated
the migration and tube formation of human ECFCs as potent as the whole periostin. Chemotactic migration of
ECFCs induced by the full length and the ﬁrst FAS-1 domain of periostin was abrogated by blocking antibodies
against β3 and β5 integrins. Intramuscular injection of the full length and the ﬁrst FAS-1 domain of periostin
into the ischemic hindlimb of mice attenuated severe limb loss and promoted blood perfusion and homing of in-
travenously administered ECFCs to the ischemic limb. These results suggest that theﬁrst FAS-1 domain is respon-
sible for periostin-induced migration and angiogenesis and it can be used as a therapeutic tool for treatment of
peripheral artery occlusive disease by stimulating homing of ECFCs.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Peripheral artery disease (PAD) is a common vascular disease that
not only affects the quality of life but also increases the risk of cardiovas-
cular events. PAD can develop in association with any disease causing
stenosis or occlusion of the lower limb arteries; atherosclerosis disease
is the most common etiology. PAD has been reported in diverse races
in 3–10% of people aged younger than 70 years and in 15–20% of people
older than 70 years. One in ﬁve patients older than 65 years had either
symptomatic or asymptomatic peripheral arterial disease. One third of
PAD patients tend to have a complete occlusion of a major artery to
the leg as they age. Patients with diabetic peripheral arterial disease
are at the highest risk of progression toward critical limb ischemia,le; ECFCs, endothelial colony
, peripheral artery disease
gy, School of Medicine, Pusan
o, Republic of Korea. Tel.: +82have a 10 times greater possibility of requiring amputation, and have
a prevalence of gangrene 20–30 times higher than that of the general
population [1]. Therapeutic angiogenesis is important for blood perfu-
sion in ischemic tissues and tissue repair after critical ischemia [2–5].
Endothelial colony forming cells (ECFCs) were ﬁrst isolated from the
adult peripheral blood in 1997 [6]. ECFCs were also identiﬁed in the
bone marrow and other tissues, representing a highly pro-angiogenic
pool of cells liable to accumulate into foci of physiological and patholog-
ical neovascularization [6,7]. ECFCs exhibit characteristics usually asso-
ciated to common stem/progenitor cells. It is thought that ECFCs are
able to maintain their immature state and, upon an encounter with ap-
propriate stimuli, they are able to migrate, proliferate, or differentiate
into endothelial cells. In addition, ECFCs can also contribute directly to
regenerative processes or at least support the regeneration of the in-
jured cardio-vascular system [8]. Prior studies have shown that utiliza-
tion of ECFCs is an encouraging approach for therapeutic applications as
they may release angiogenic cytokines and participate in vascular re-
generation [9]. A number of clinical and experimental trials have dem-
onstrated the safety and feasibility of ECFC-based therapy in animal
models of ischemia, such as critical limb ischemia and cardiovascular
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is limited due to poor engraftment and homing ability of transplanted
ECFCs into ischemic tissues [12]. To improve the therapeutic potential
of ECFCs, it is necessary to improve homing and engraftment potentials
of transplanted ECFCs.
Periostin, originally identiﬁed as an osteoblast-speciﬁc factor-2, is a
93-kDa extracellular matrix protein, which shares a homology with
the insect cell adhesion molecule fasciclin I (FAS-1). High expression
of periostin in the periodontal ligament and the periosteumhas been re-
ported [13]. Periostin is involved in the regulation of cell adhesion and
motility through an integrin-dependentmechanism [14]. Periostin pos-
sesses an N-terminal EMI domain which promotes the formation of
multimers in non-reducing conditions, a tandem repeat of four FAS-1
domains which act as ligands for integrins, and a C-terminal domain
which regulates cell–matrix organization and interactions by binding
extracellular matrix proteins [13]. Periostin was reported to bind the
integrins αvβ3, αvβ5, and α6β4, thereby promoting activation of di-
verse signaling pathways, including phosphoinositide-3-kinase-Akt,
MEK–MAPK, and Src [15]. The functions of periostin are associated
with skeletal development, heart development, and cancer [16–18].
Periostin promoted angiogenesis, migration, and invasion of human
umbilical endothelial cells [19] and stimulated tumor angiogenesis in
breast cancer [20]. These results suggest the potential for application
of periostin in therapeutic angiogenesis of PAD and regulation of angio-
genic activities of ECFCs.
In this study, we attempted to determine whether periostin can en-
hance angiogenic activities of ECFCs in vitro and in vivo. We identiﬁed
the ﬁrst FAS-1 domain as the functional domain of periostin implicated
in the periostin-stimulated angiogenic activities of ECFCs. In addition,
we explored the effects of the ﬁrst FAS-1 domain of periostin in the re-
generation and neovascularization of the ischemic limb and in vivo
homing ability of transplanted ECFCs.
2. Materials and methods
2.1. Materials
Fetal bovine serum, trypsin, and CellTracker™ CM-DiI (CM-DiI)
were purchased from Invitrogen (Carlsbad, CA). Endothelial Growth
Medium-2 bullet kit was purchased from Lonza (Basel, Swiss). Culture
plates were purchased from Nunc (Roskilde, Denmark). A recombinant
human periostin protein was purchased from R&D Systems, Inc.
(Minneapolis, MN). Anti-α-SMA antibody (ab5694) was purchased
from Abcam PLC (Cambridge, UK). Anti-CD31 rat antibody (MEC 13.3)
and growth factor-reduced Matrigel™were purchased from BD Biosci-
ences (Franklin Lakes, NJ). Peroxidase-labeled secondary antibodies and
Enhanced Chemiluminescence Western blotting system were pur-
chased from Amersham Biosciences (Piscataway, NJ).
2.2. Expression and puriﬁcation of recombinant periostin proteins
For the expression of functional domains of periostin as recombinant
His6-tagged proteins, four FAS-1 and C-terminal domains of human
periostin were subcloned into a pET-30a expression vector (Novagen,
Madison, WI) by ligation of PCR-generated cDNA fragments containing
additional EcoRI and Hind III sites into the pET-30a vector. The amino
acid sequences of the ﬁve domains of periostin are as follows: the ﬁrst
FAS-1 (representing amino acids 94 to 234), the second FAS-1 (amino
acids 232 to 368), the third FAS-1 (amino acids 364 to 496), the fourth
FAS-1 (amino acids 491 to 634), and the C-terminal domain (amino
acids 627 to 780). We named these ﬁve fragments “domains 1 to 5” as
shown in Fig. 1A. The His-tagged recombinant proteins were expressed
in BL21 (DE3) cells, andwere harvested and puriﬁed using a nickel-NTA
agarose column (Qiagen, Inc., Valencia, CA) as described in the instruc-
tion manual. Endotoxin was removed using Detoxi-Gel Endotoxin Re-
moving Gel (Pierce, Rockford, IL), and the removal of endotoxin wasconﬁrmed by Limulus Amebocyte Lysate test (Cape cod, East Falmouth,
MA). The puriﬁed recombinant proteins were loaded onto 15% sodium
dodecyl sulfate-acrylamide gel for electrophoresis and stained with
Coomassie Brilliant Blue staining.2.3. Cell culture
Human ECFCs were isolated from the human umbilical cord blood,
which was collected in disposable sterile pyrogen-free bags (Green
Cross, Yongin, Korea) containing anticoagulant. Written informed con-
sent was obtained from all donors and the study was approved by the
Institutional ReviewBoard of PusanNational UniversityHospital.Mono-
nuclear cells were isolated from the blood with Histopaque-1077
(Sigma-Aldrich, Switzerland) as described previously [21]. Human um-
bilical vein endothelial cells were purchased from Lonza (Allendale, NJ).
Both ECFCs and human umbilical vein endothelial cells were seeded on
culture dishes coatedwith 0.1% gelatin (Sigma-Aldrich) andmaintained
in endothelial cell basal medium-2 (EBM-2) (Clonetics, San Diego, CA)
supplementedwith EGM-2MVSingle Quotes containing 5% fetal bovine
serum (FBS), humanVEGF-1, humanﬁbroblast growth factor-2 (FGF-2),
human epidermal growth factor (EGF), insulin-like growth factor-1
(IGF-1), and ascorbic acid. After four days in culture, non-adherent
cells were removed and adherent cells were trypsinized and re-plated
at a density of 1 × 106 per well until day 7 [22].2.4. Cell migration assay
Assay for the migration of ECFCs was performed using a disposable
96-well chemotaxis chamber (Neuro Probe, Inc., Gaithersburg, MD).
Brieﬂy, ECFCs were harvested with 0.05% trypsin containing 0.02%
EDTA, washed once, and suspended in EBM-2 at a concentration of 1 ×
105 cells/ml. A membrane ﬁlter with 8-μm pores for the chemotaxis
chamber was pre-coated overnight with 20 μg/ml rat-tail collagen at
4 °C; an aliquot (50 μl) of ECFC suspension was loaded into the upper
chamber, and EBM-2 supplemented with recombinant proteins of
periostin was then placed in the lower chamber. Following incubation
of the cells for 12 h at 37 °C, the ﬁlters were disassembled, and the
upper surface of each ﬁlter was scraped free of cells by wiping it with a
cotton swab. The number of cells that had migrated to the lower surface
of each ﬁlter was determined by counting the cells in four locations
under microscopy at 100× magniﬁcation after staining with Hoechst.
To clarify the involvement of integrins in the periostin-stimulated
migration of ECFCs, cells were pre-incubated with function-blocking
monoclonal antibodies speciﬁc to different types of integrins, such as
integrins β1 (HMβ1-1, BioLegend), β3 (F11, BD), and β5 (P1F6,
Millipore), or control antibody (each 5 μg/ml) at 37 °C for 30 min. The
antibody-incubated cells were then loaded into the upper chamber of
a 96-well chemotaxis chamber pre-coated with rat-tail collagen, and
migration of ECFCs was determined after incubation with recombinant
periostin proteins for 12 h.2.5. Cell adhesion assay
Ninety-six-well microculture plates (Falcon, Becton-Dickinson,
Mountain View, CA) were incubated with recombinant periostin pro-
teins or recombinant periostin domains 1 to 5 at 37 °C for 1 h, followed
by blocking with PBS containing 0.2% BSA for 1 h at 37 °C. Cells were
trypsinized and suspended in the culture media at a density of 2 ×
105 cells/ml, and 0.1 ml of the cell suspension was then added to each
well of the plate. Analysis of cell attachment was performed as follows.
After incubation for 1 h at 37 °C, unattached cellswere removed by rins-
ing twice with PBS. The number of attached cells was determined by
counting the cells under microscopy at 100× magniﬁcation after stain-
ing with hematoxylin and eosin.
Fig. 1. Periostin stimulates themigration of ECFCs through theﬁrst FAS-1 domain. (A) Schematic diagram of human periostin and its ﬁve truncated protein constructs (D1, D2, D3, D4, and
D5). (B) SDS-PAGE and Coomassie Brilliant Blue staining of the ﬁve periostin fragments. (C) Effects of the full length (FL) and the ﬁve fragments of periostin on migration of ECFCs.
Chemotactic migration of ECFCs was determined after treatment with VEGF (10 ng/ml), full length recombinant periostin (10 μg/ml), or ﬁve fragments of periostin (each 10 μg/ml).
(D) Dose-dependent effect of theﬁrst FAS-1 domain of periostin (periostinD1) on chemotacticmigration of ECFCs.Migration of ECFCs in response to increasing concentrations of periostin
D1 fragment was quantiﬁed. Data represent mean ± S.D. (n = 5). *, p b 0.01; #, p b 0.05 vs control.
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Human ECFCs were maintained in a 37 °C, 5% CO2 humidiﬁed envi-
ronmental chamber. The cells were grown in an Endothelial Growth
Medium-2 bullet kit (Lonza) according to the manufacturer's instruc-
tions. For tube formation assay of ECFCs, aliquots (50 μl) of growth
factor-reduced Matrigel (10 mg protein/ml) were added to 96-well
culture dishes and polymerized for 30 min at 37 °C. ECFCs were
trypsinized, resuspended in EBM-2 basal medium supplanted with 1%
FBS, and plated onto a layer of Matrigel at a density of 1 × 105 cells/
well. The cells were then exposed to EBM-2 media with 1% FBS or re-
combinant periostin domains 1 to 5. After incubation of the Matrigel
cultures at 37 °C for 9 h, the cultures were photographed using an
inverted microscope with a digital camera.2.7. Hindlimb ischemia, cell transplantation, and blood ﬂow measurement
Animal experiments were performed using protocols approved by
the Pusan National University Institutional Animal Use and Care Com-
mittee. C57BL/6J mice (male, age 8–10 wks, weighing 22–24 g) were
anesthetized with an intraperitoneal injection of 400 mg/kg 2,2,2-
tribromoethanol (Avertin; Sigma) for operative resection of one femoral
artery and laser Doppler perfusion imaging. To determine the effects of
the full length or theﬁrst FAS-1 domain of periostin on in vivo blood per-
fusion and tissue necrosis in ischemic limbs, eight different mice per
each experimental group were injected with the recombinant proteins.
The femoral artery was excised from its proximal origin as a branch
of the external iliac artery to the distal point where it bifurcates into
the saphenous and popliteal arteries. After arterial ligation, ischemic
hindlimbs were injected with the full length or fragments of periostin
into three sites (20 μl/each site) of the gracilis muscle in the medial
thigh three times per week. The extent of necrosis in the ischemic
hindlimb was recorded on day 28 after surgery. Scores for necrosiswere assessed as follows: 0, limb salvage; 1, toes amputation; 2,
foot amputation; and 3, limb amputation. Blood ﬂow of the ischemic
and normal limbs was measured using a laser Doppler perfusion im-
aging (LDPI) analyzer (Moor instruments, Devon, UK) on days 0, 7,
14, 21, and 28 after induction of hindlimb ischemia. Perfusion of
the ischemic and non-ischemic limbs was calculated on the basis
of colored histogram pixels. Red and blue colors indicate high and
low perfusion, respectively. Blood perfusion is expressed as the
LDPI index representing the ratio of the ischemic versus non-
ischemic limb blood ﬂows. A ratio of 1 before surgery indicates
equal blood perfusion of both legs.
2.8. Histological and immunoﬂuorescence analyses
For histological and immunostaining of the tissue specimens,
hindlimb muscles were removed, formalin-ﬁxed, and parafﬁn-
embedded. Three 6 μm-thick sections were taken from the
parafﬁn-embedded specimens at 150 μm intervals, stained with
hematoxylin and eosin (H&E), observed, and photographed with a
microscope (Axioimager M2, Carl Zeiss, Heidenheim, Germany).
Masson's trichrome collagen stainingwas also performed for the assess-
ment of tissue ﬁbrosis in ischemic regions. Endothelial cells and smooth
muscle cells were immunostained with rabbit anti-CD31 and rabbit
anti-α-SMA antibodies. Inﬂammatory cells were stained with rat anti-
CD68 antibody (AbD Serotec, Raleigh, NC). The specimens were incu-
batedwith Alexa 488 goat anti-rat or Alexa 568 goat anti-rabbit second-
ary antibodies (Life Technologies, Carlsbad, CA), followed by washing
and mounting in Vectashield medium (Vector Laboratories) with 4′,6-
diamidino-2-phenylindole (DAPI) for visualization of nuclei. The
stained sections were visualized by laser scanning confocal microscopy
(Olympus FluoView FV1000). Capillary density, the number of arteri-
oles/arteries, and the number of proliferating cells were assessed by
counting the number of CD31-positive and α-SMA-positive features
per high power ﬁeld (400×). Twelve randomly chosen microscopic
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the number of capillary density and α-SMA-positive arteries for each
mouse.
2.9. Cell tracking analysis
For tracking of ECFCs into ischemic tissues, the effects of recombi-
nant periostin proteins on homing of intravenously transplanted
ECFCs into the ischemic limbs of BALB/CA-nu/nu athymic nude mice
(age 8–10wks andweighing 17–22 g; eightmice per each experimental
group) were determined. ECFCs were labeled with the long-lasting cell
tracker CM-DiI according to the manufacturer's instructions. CM-DiI-
labeled ECFCs (1 × 106 cells) were transplanted into the hindlimb
ischemia animal model by intravenous injection into the tail vein,
followed by direct injection of recombinant periostin proteins or PBS
(60 μl each) into the ischemic limbs. For quantitative analyses, three sec-
tions measuring 6 μm in thickness were taken from the specimens at
150 μm intervals. CM-DiI-labeled cells were counted in three randomly
selected microscopic ﬁelds from serial sections in each tissue block.
2.10. Statistical analysis
Results of multiple observations are presented as mean ± SD. For
multivariate data analysis, one-way or two-way ANOVA, followed by
Scheffé's post hoc test, was used for assessment of group differences.
3. Results
3.1. Periostin promotes migration of ECFCs through the ﬁrst FAS-1 domain
To identify the functional domains involved in periostin-stimulated
angiogenesis, we generated ﬁve fragments of periostin (Fig. 1A). The re-
combinant proteins were over-expressed as His-tagged proteins in
Escherichia coli and puriﬁed using Ni-NTA afﬁnity chromatography,
and the purity of the puriﬁed periostin domainswas estimated to be ap-
proximately 90% (Fig. 1B).
To determine whether periostin has pro-angiogenic potential, we
performed a transwell migration assay in order to examine the effects
of the recombinant full length periostin and its ﬁve fragments on the
migration of ECFCs. As shown in Fig. 1C, the full length periostin stimu-
lated migration of ECFCs as potent as VEGF, which was previously re-
ported as a chemotactic factor for ECFCs [8]. We found that the ﬁrst
FAS-1 domain of periostin, but not other domains, induced signiﬁcant
stimulation of the chemotactic migration ability of ECFCs, and that the
stimulatory effect of the ﬁrst FAS-1 domain of periostin was as potent
as that of the full length periostin protein (Fig. 1C). In addition, the
ﬁrst FAS-1 domain of periostin induced dose-dependent augmentation
of ECFC migration with maximal stimulation at 10 μg/ml, and then de-
clined at a concentration of 25 μg/ml (Fig. 1D).Fig. 2. Effects of the full length and the ﬁrst FAS-1 domain of periostin on the adhesion of ECFCs
plateswere coatedwith the full length periostin (FL) or theﬁve fragments of periostin (10 μg/m
FAS-1 domain of periostin (periostin D1) on adhesion of ECFCs. Data represent mean ± S.D. (n3.2. The ﬁrst FAS-1 domain of periostin stimulates adhesion of ECFCs
Because periostin is an extracellular adhesion molecule, we next ex-
plored the effect of periostin on the adhesive capacity of ECFCs. Pre-
coating of 96-well culture plates with recombinant periostin resulted
in enhanced adhesion of ECFCs onto culture plates. In addition, coating
with the ﬁrst FAS-1 domain of periostin, but not other periostin do-
mains, resulted in signiﬁcant enhancement of the adhesive capacity of
ECFCs (Fig. 2A). In addition, the ﬁrst FAS-1 domain of periostin induced
a dose-dependent increase in the adhesive capacity of ECFCs with a
maximal stimulation at a concentration of 10 μg/ml (Fig. 2B). These re-
sults suggest that the ﬁrst FAS-1 domain of periostin is responsible for
periostin-stimulated adhesion of ECFCs.3.3. The ﬁrst FAS-1 domain of periostin stimulates endothelial tube formation
of human ECFCs in vitro
To investigate the angiogenic activities of the ﬁrst FAS-1 domain of
periostin, the effects of the full length and the ﬁve domains of periostin
on tube forming ability of ECFCs were determined. Treatment of ECFCs
with the full length periostin protein stimulated capillary-like tube for-
mation in ECFCs. In addition, the ﬁrst FAS-1 domain, but not other frag-
ments of periostin, induced signiﬁcant stimulation of tube forming
ability of ECFCs (Fig. 3A and B). Endothelial tube formation induced by
the ﬁrst FAS-1 domain of periostin was maximally stimulated by treat-
ment of ECFCs with a 2 μg/ml concentration (Fig. 3C), while migration
and adhesion of ECFCs were maximally stimulated by treatment with
10 μg/ml of the ﬁrst FAS-1 domain of periostin. Endothelial tube forma-
tion of ECFCs was signiﬁcantly induced in response to treatment with
the full length or the ﬁrst FAS-1 domain of periostin as it was with
VEGF treatment. Endothelial tube formation and maturation were ob-
served over 9–16 h, and the capillary-like structure was maintained
over 24 h (Supplemental Fig. 1).3.4. Role of integrins β3 and β5 in the periostin-induced migration of ECFCs
Periostin has been reported to activate various cellular responses by
activation of integrins αvβ3 and αvβ5 [20]. To explore the involvement
of integrins in periostin-stimulated cellular responses, ECFCs were
pre-incubated with function-blocking antibodies against β1, β3, and
β5 integrins, followed by measurement of cell migration in response
to the full length and the ﬁrst FAS-1 domain of periostin. Pre-
incubation of ECFCs with antibodies against integrin β3 or β5 resulted
in markedly attenuated cell migration stimulated by the full length or
the ﬁrst FAS-1 domain of periostin; however, incubation with anti-β1
antibody did not result in the abrogation of periostin-stimulated cellmi-
gration (Fig. 4). This result suggests involvement of β3 and β5 integrins
in ECFCmigration induced by the full length or the ﬁrst FAS-1 domain of
periostin.. (A) Stimulation of ECFC adhesion by the ﬁrst FAS-1 domain of periostin. 96-Well culture
l), followed by the determination of ECFC adhesion. (B) Dose-dependent effects of theﬁrst
= 4). * indicates p b 0.05 vs control.
Fig. 3. Effects of the full length and the ﬁrst FAS-1 domain of periostin on the tube formation of ECFCs. (A) Representative images of the tube formation of ECFCs in response to the full
length (FL) or the ﬁve fragments of periostin (each 10 μg/ml). (B) Tube formation was quantiﬁed bymeasuring the length of tubes in four random ﬁelds from each well and normalizing
the values relative to those of the corresponding control. (C) Dose-dependence of periostin D1 on tube forming ability of ECFCs. Data representmean± S.D. (n= 8). * indicates p b 0.05 vs
control.
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ischemic hindlimb and inhibits ischemic tissue damage
Because the full length and the ﬁrst FAS-1 domain of periostin en-
hanced migration, adhesion, and tube formation of ECFCs in vitro, we
next examined the effects of the full length and the ﬁrst FAS-1 domain
of periostin on in vivo angiogenesis and ischemic tissue damage in amu-
rine model of hindlimb ischemia. The full length or the ﬁrst FAS-1 do-
main of periostin was injected intramuscularly into the ischemic
hindlimb, and blood ﬂow was measured over a period of four weeks
using an LDPI analyzer. Intramuscular injection of the full length or
the ﬁrst FAS-1 domain of periostin into the ischemic hindlimb resultedFig. 4. Effects of function-blocking antibodies against integrinsβ1,β3, andβ5 on ECFCmigra-
tion. hECFCs were pre-incubated with control antibody or function-blocking antibodies
against integrins β1, β3, or β5, followed by the determination of cell migration in response
to the full length (periostin FL) periostin or the ﬁrst FAS-1 domain of periostin (periostin
D1) (each 10 μg/ml). Data represent mean ± S.D. (n = 6). * indicates p b 0.05 vs control.in signiﬁcantly improved blood perfusion, as determined by LDPI
(Fig. 5A and B). In addition, injection of the full length or the ﬁrst FAS-
1 domain of periostin resulted in signiﬁcantly attenuated tissue necrosis
and amputation as comparedwith control groups at fourweeks after in-
duction of ischemia (Fig. 5C).
To determine whether injection of the full length or the ﬁrst FAS-1
domain of periostin can stimulate angiogenesis in vivo, we performed
immunostaining for determination of densities of CD31-positive capil-
laries andα-SMA-positive arteries/arterioles in ischemicmuscles. Intra-
muscular injection of recombinant periostin protein time-dependently
increased the numbers of CD31-positive capillaries and α-SMA-
positive blood vessels compared with control group in the ischemic
hindlimb (Supplemental Fig. 2A–D). The density of CD31-positive capil-
laries was signiﬁcantly higher in the ischemic limb injectedwith the full
length or the ﬁrst FAS-1 domain of periostin than that of the control
groups injected with saline buffer (Fig. 6A and B). In addition, the num-
bers ofα-SMA-positive blood vessels in the ischemic limb injected with
the full length or the ﬁrst FAS-1 domain of periostin were greater than
those of the control groups (Fig. 6A and C). The increased numbers of
CD31-positive capillaries and α-SMA-positive arterioles/arteries after
injection of the full length or the ﬁrst FAS-1 domain of periostin corre-
late with the increased blood perfusion in the ischemic limb injected
with the full length or the ﬁrst FAS-1 domain of periostin. The ischemic
hindlimbs exhibited massive myoﬁber damage, inﬂammatory cell inﬁl-
tration, and tissue ﬁbrosis; however, intramuscular injection of the full
length or the ﬁrst FAS-1 domain of periostin attenuated the necrosis
and ﬁbrosis of the ischemic limbs (Supplemental Fig. 2E and A). More-
over, inﬁltration of CD68+ monocytes/macrophages was inhibited in
the ischemic limbs by injection of the full length or the ﬁrst FAS-1 do-
main of periostin (Supplemental Fig. 3B and C). Injection of recombi-
nant periostin proteins did not affect muscle architecture and ﬁbrosis
status in the normal hindlimbs (Supplemental Fig. 3D). These results
Fig. 5. Effects of the full length and the ﬁrst FAS-1 domain of periostin on blood perfusion and limb salvage in an ischemic hindlimb animalmodel. The full length (periostin FL) or the ﬁrst
FAS-1 domain (periostin D1) of periostin (60 μg/each limb) was administered by intramuscular injection into the ischemic hindlimbs three times per week for a period of four weeks.
(A) Representative images of the hindlimbs and blood ﬂow measured by LDPI on days 0 and 28 from eight different mice. (B) Quantitative analysis of blood ﬂow measured by LDPI.
The LDPI ratiowas calculated as the ratio of ischemic to contralateral hindlimb blood perfusion over the observation period. Data representmean± S.D. (n=8 per each group). * indicates
p b 0.05 periostin FL and D1 vs control. (C) Statistical analysis of the necrosis score on day 28. Data represent mean ± S.D. (n = 8 per group). * indicates p b 0.05 vs control.
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domain of periostin provides protection from tissue necrosis and exces-
sive inﬂammation in the ischemic hindlimb by stimulating blood
perfusion.3.6. Periostin stimulates homing and engraftment of ECFCs into the ischemic
limb
To determine whether periostin can stimulate homing and engraft-
ment of ECFCs in vivo, we examined the effects of the full length and
the ﬁrst FAS-1 domain of periostin on homing and engraftment of
ECFCs into the ischemic limb in vivo. To trace the engraftment of
ECFCs into the ischemic limb, ECFCs were labeled with the ﬂuorescent
dye CM-DiI, followed by i.v. injection of CM-DiI-labeled ECFCs and intra-
muscular injection of the full length or the ﬁrst FAS-1 domain of
periostin into the ischemic limbs. Sections of the ischemic hindlimb
muscle were visualized under a confocal microscope, and engraftment
of administered ECFCs was quantiﬁed on day 3 after i.v. injection of
CM-DiI-labeled ECFCs. As shown in Fig. 7A, CM-DiI-positive cells were
overlaid with CD31-positive cells in the ischemic limbs, suggesting
incorporation of transplanted ECFCs into CD31-positive capillaries.
The numbers of CM-DiI- and CD31-positive endothelial cells in the
hindlimbs injected with the full length or the ﬁrst FAS-1 domain of
periostin were signiﬁcantly higher than those in the control hindlimbs
(Fig. 7A). In addition, engraftment of CM-DiI-labeled cells into the ische-
mic limbswas stimulated by intramuscular injection of the full length or
the ﬁrst FAS-1 domain of periostin (Fig. 7A and B). These results suggest
that periostin promotes homing and engraftment of ECFCs into the is-
chemic limbs through the ﬁrst FAS-1 domain-dependent mechanism.4. Discussion
In the current study, we demonstrated that periostin stimulated an-
giogenic capacity of ECFCs, such asmigration, adhesion, and tube forma-
tion through the ﬁrst FAS-1 domain-dependent mechanism. Periostin
has been known to stimulate angiogenic activity of endothelial cells
[20,23]. Periostin plays a key role in the pathogenesis and progression
of cardiac valve diseases by controlling angiogenesis [24]. In addition,
periostin stimulated proliferation, migration, and lymphangiogenesis
of lymphatic endothelial cells [25]. Moreover, periostin increased the
sensitivity of endothelial cells to vascular endothelial growth factor
through induction of VEGFR-2 expression [20]. We found that the full
length and the ﬁrst FAS-1 domain of periostin stimulated the endothe-
lial tube formation of ECFCs and human umbilical vein endothelial
cells (Supplemental Fig. 4). Therefore, it is likely that both ECFCs and
tissue-resident endothelial cells are implicated in the periostin-
stimulated vasculogenesis and angiogenesis in the ischemic limb. Al-
though engraftment of administered ECFCs into the ischemic limbs
was markedly stimulated by intramuscular injection of recombinant
periostin, the percentages of CM-DiI-positive ECFCs incorporated into
newly formed capillarieswere quite low in the ischemic limb. The abso-
lute number of incorporated ECFCs has been reported to drastically vary
between 0% and 90% in the different studies [26]. Therefore, it is still un-
clear whether newly formed capillaries are originated from ECFCs, and
the origin of endothelial cells in capillaries needs to be clariﬁed further.
The FAS-1 domain of βig-h3 (TGF-β-induced protein) has been re-
ported to inhibit vascular endothelial growth factor-induced growth
and migration of endothelial cells by inhibiting the association of
αvβ3 integrin with vascular endothelial growth factor receptor-2 [27].
Five fragments of periostin including the ﬁrst FAS-1 domain, however,
Fig. 6. Effects of the full length and theﬁrst FAS-1 domain of periostin on neovascularization in the ischemic hindlimb. (A) Immunostaining of CD31-positive capillaries (green) orα-SMA-
positive blood vessels (red) in the ischemic limbs on day 28 after intramuscular injection of PBS (control), periostin FL, or periostin D1. Nuclei (blue) were counterstained with DAPI,
and overlaid images are shown. Scale bar = 50 μm. (B) Quantitative analysis of capillary density expressed by the number of CD31-positive capillaries per high power ﬁeld (HPF).
(C) Quantitative analysis of α-SMA-positive vessels per HPF. Data represent mean ± S.D. (n = 24). * indicates p b 0.05 vs control.
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(Supplemental Fig. 5), which suggests that each domain of periostin
does not act as a dominant negative for the full length periostin.
Function-blocking antibodies against integrin β3 and β5 subunits abro-
gated the cell migration stimulated by the full length or the ﬁrst FAS-1
domain of periostin. It has been suggested that the FAS-1 domain of
periostin is responsible for the direct interaction of periostinwith sever-
al integrins, includingαvβ3 andαvβ5 [16]. Periostin promoted the adhe-
sion and migration of ovarian epithelial cells through the activation of
αvβ3 and αvβ5 integrins [14]. Periostin mediated the migration of vas-
cular smooth muscle cells through the integrins αvβ3 and αvβ5 and
focal adhesion kinase pathway [28]. In addition,αvβ3 integrinmediated
the periostin-stimulated expression of MMP-2 [29]. DNA aptamer di-
rected against human periostin caused disruption of the interaction be-
tween periostin and its cell surface receptors, αvβ3 or αvβ5 integrins
[30]. The anti-periostin aptamer induced marked attenuation of the
periostin-induced adhesion, migration, and invasion of breast cancer
cells by blocking the activation of integrin receptor-mediated signaling.These results support those of the current study, indicating that αvβ3
and αvβ5 play a critical role in the stimulation of angiogenic activities
of ECFCs by direct interaction with periostin.
In this study, we demonstrated that the full length or the ﬁrst FAS-1
domain of periostin signiﬁcantly improved blood perfusion and attenu-
ated tissue necrosis in the ischemic limbs, compared with the control
group. In addition, the numbers of CD31-positive capillaries and α-
SMA-positive arteries were increased in the ischemic limbs injected
with the full length or the ﬁrst FAS-1 domain of periostin. Recombinant
periostin protein has been reported to stimulate the proliferation of
cardiomyocytes in vitro and promoted cardiac repair and angiogenesis
after myocardial infarction [31], whereas periostin knockout mice ex-
hibited impaired cardiac healing after acute myocardial infarction [32].
Periostin-deﬁcientmice exhibited delayed in vivowound repair, and di-
rect administration of exogenous periostin resulted in improvedwound
repair [33]. Periostin-overexpressingmesenchymal stem cells improved
cardiac function compared tomesenchymal stem cell-injected controls,
when they were injected into the infarcted myocardium [34]. These
Fig. 7. Effects of the full length and the ﬁrst FAS-1 domain of periostin on the engraftment of ECFCs. (A) ECFCs were labeled with CM-DiI and injected intravenously with intramuscular
injection of PBS (control), periostin FL, or periostin D1. Tissue sections of the ischemic hindlimb of day 3 after ECFC injection were immunostained with anti-CD31 antibody. Overlaid im-
ages of CM-DiI-positive ECFCs (red color), nuclei (blue color), and CD31-positive endothelial cells (green color) are shown. (B)Quantitative analysis of thenumber of CM-DiI-labeled ECFCs
per HPF. Data represent mean ± S.D. (n = 24). * indicates p b 0.05 vs control.
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tissues. Intrapericardial delivering of recombinant peptide consisting of
the four FAS-1 domain of human periostin stimulatedmyocardial repair
but increasedmyocardialﬁbrosis in a pigmodel ofmyocardial infarction
[35]. Furthermore, periostin has been reported to promote ﬁbrosis in
polycystic kidney disease and in an animal model of idiopathic pulmo-
nary ﬁbrosis [36,37]. In the present study, we showed that the intra-
muscular injection of recombinant periostin attenuated tissue ﬁbrosis
and excessive inﬂammation in the ischemic limbs. Themolecular mecha-
nism of reduced ﬁbrosis in the ischemic limbs injected with recombinant
periostin proteins is still unclear.Whilemacrophages are beneﬁcial to the
repair of normally healing wounds, they may promote excessive inﬂam-
mation and ﬁbrosis in certain circumstances [38]. Therefore, it is likely
that increased blood perfusion can prevent tissue necrosis and excessive
inﬂammation which may lead to tissue ﬁbrosis.
Periostin has been known to be expressed in response to tissue inju-
ry, including myocardial infarction and cutaneous wound [39]. It has
been reported that periostin expression was strongly up-regulated in
the granulation tissues of thewounded skin, whereas it could be detect-
ed at the low level in the dermal-epidermal junction and around the
hair follicles in the normal unwounded skin [33]. Consistently, we
found that periostin expression was induced in the granulation tis-
sues of the wounded skin (Supplemental Fig. 6). In contrast, we
could not detect the expression of periostin in the muscle tissues
of the normal hindlimbs and ischemic hindlimbs. These results
suggest that periostin expression can be induced in the wounded
skin but not in the ischemic limbs. Therefore, it is likely that the
therapeutic effect of recombinant periostin protein does not simply ac-
centuate a naturally-occurring process but stimulate the regenerative
function of ischemic tissues.
Intramuscular injection of the full length or the ﬁrst FAS-1 domain of
periostin stimulated homing of intravenously transplanted human
ECFCs into the ischemic limbs and incorporation of ECFCs into newly
formed CD31+ capillaries. Various angiogenic factors, such as VEGF,
SDF-1α, and insulin-like growth factor2 (IGF2), all of which are
up-regulated in hypoxic condition, have been reported to regulate re-
cruitment of ECFCs [40]. Even though the intra-arterial injection ofVEGF promotes revascularization in a rabbit ischemic hindlimb model
[41], local delivery of VEGF-A may increase the risk of plaque destabili-
zation in advanced atherosclerosis [42]. In myocardial infarction, up-
regulation of SDF-1α occurs immediately after the introduction of in-
farction; however, it is down-regulated within seven days [43]. Accord-
ing to the results of our study, periostin promoted the adhesion of ECFCs
through the activation of β3 or β5 integrins. Integrins represent a major
molecular determinant of ECFC function, with different integrin sub-
units regulating different steps of ECFC biology. Speciﬁcally, integrin
α4β1 is a key regulator of ECFC retention and/or mobilization from the
bone marrow, while integrinsα5β1,α6β1,αvβ3, and αvβ5 are major de-
terminants of ECFC homing, invasion, differentiation, and paracrine fac-
tor secretion [44]. Integrin αvβ3 has been reported to play a key role in
angiogenesis by regulating migration and adhesion of ECFCs in an ische-
mic hindlimb animalmodel [45]. In addition, integrin-mediated adhesion
to the extracellular matrix is essentially required for the incorporation of
circulating ECFCs into the blood vessels and differentiation into the endo-
thelial cells [46]. Speciﬁcally,αvβ3 andαvβ5 integrins play a pivotal role in
ECFC adhesion to denuded vessels and re-endothelialization of denuded
arteries [47]. These results support those of the current study showing
that periostin-induced activation of integrins plays a critical role in the
neovascularization of ischemic tissues by eliciting migration, adhesion,
and tube formation of ECFCs.
Numerous clinical trials evaluating the therapeutic effects of circu-
lating ECFCs are currently in progress [48]. However, most patients un-
dergoing ECFC therapy for ischemic diseases have backgroundproblems
hindering the efﬁcacy of autologous ECFC therapy. Therefore, ﬁnding
extracellular factors to enhance the recruitment of ECFCs into ischemic
tissues brings scientiﬁc understanding of ECFC biology aswell as provid-
ing a tool for treatment of ischemic diseases. Compared to the full length
periostin, the ﬁrst FAS-1 domain of periostin could be highly expressed
in E. coli and large amounts of the FAS-1 domain peptide of periostin
could be efﬁciently puriﬁed to homogeneity. Therefore, the ﬁrst FAS-1
domain peptide can be used for the enhancement of therapeutic efﬁcacy
of ECFCs in treatment of ischemic diseases, such as peripheral arterial
diseases,myocardial infarction, and stroke, by stimulating the therapeu-
tic potential of endogenous or transplanted ECFCs.
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